Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.

MSD's Sac-TMT presents as a strong competitor to AstraZeneca/Daichii Sankyo's Dato-DXd based on cross-trial comparisons.

Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitorOS of 15.6 ...

Endogenous retroviruses (ERVs) are remnants of ancient exogenous retroviruses that integrated into the germline of ancestral humans. They inherit vertically according to the Mendelian inheritance ...

It is a third-generation antibody-drug conjugate that acts by targeting cells expressing (trophoblast antigen) TROP2. It is administered through intravenous route in the form of powder. The drug ...

Studying human embryonic development is complicated for several reasons. Models derived from pluripotent stem cells ...

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the ...

Median overall survival of 15.6 months in Phase 2 Bria-IMT study patients treated in combination with immune checkpoint inhibitorOS of 15.6 months compares favorably with 6.7-9.3 months reported for ...